Literature DB >> 8636387

The production of an amyloidogenic metabolite of the Alzheimer amyloid beta precursor protein (APP) in thyroid cells is stimulated by interleukin 1 beta, but inhibited by interferon gamma.

T L Schmitt1, E Steiner, P Klinger, A Sztankay, B Grubeck-Loebenstein.   

Abstract

Thyroid epithelial cells have been shown to have a high APP expression and to produce large amounts of its metabolic derivatives, namely secreted APPs and a potentially amyloidogenic 41-kDa C-terminal fragment. It was the aim of the present study to analyze how APP production and metabolism were regulated in human thyroid cells. The effects of three cytokines, interferon gamma (IFN gamma), interleukin 1beta (IL-1 beta) and transforming growth factor (TGF) beta, were investigated. Cell extracts and supernatants were studied by immunoblotting using specific N- and C-terminal APP antibodies. Quantification was performed by densitometric scanning. We demonstrate that IFN gamma has a strong suppressive effect on the production and metabolism of APP. From a concentration of 30 U/ml upwards it reduces the cellular APP content, decreases the amounts of secreted APPs and inhibits the generation of the 41-kDa amyloidogenic APP fragment. In contrast, IL-1 beta has a stimulatory influence on the generation of the amyloidogenic 41-kDa APP metabolite, but does not affect the cellular holoprotein or APPs. TGFbeta has no significant effect on APP. Our results demonstrate that cytokines can regulate APP production and metabolism in thyroid cells. IFN gamma is the first naturally occurring agent described to inhibit the generation of amyloidogenic APP fragments. It may be of relevance in preventing amyloid deposition during inflammatory processes in the thyroid gland, but may exert a similar protective effect in other non-neuronal and neuronal tissues.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8636387     DOI: 10.1210/jcem.81.4.8636387

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  7 in total

Review 1.  The Role of Inflammatory Mediators in the Pathogenesis of Alzheimer's Disease.

Authors:  Gholamreza Azizi; Shadi S Navabi; Ahmed Al-Shukaili; Mir H Seyedzadeh; Reza Yazdani; Abbas Mirshafiey
Journal:  Sultan Qaboos Univ Med J       Date:  2015-08-24

2.  Juvenile rheumatoid arthritis with amyloid goiter: report of a case with review of the literature.

Authors:  A Srivastava; M Baxi; S Yadav; A Agarwal; R K Gupta; S K Misra; A Mithal
Journal:  Endocr Pathol       Date:  2001       Impact factor: 3.943

3.  Magnesium ion influx reduces neuroinflammation in Aβ precursor protein/Presenilin 1 transgenic mice by suppressing the expression of interleukin-1β.

Authors:  Pu Wang; Xin Yu; Pei-Pei Guan; Jing-Wen Guo; Yue Wang; Yan Zhang; Hang Zhao; Zhan-You Wang
Journal:  Cell Mol Immunol       Date:  2015-11-09       Impact factor: 11.530

4.  Inflammatory cytokine levels correlate with amyloid load in transgenic mouse models of Alzheimer's disease.

Authors:  Nikunj S Patel; Daniel Paris; Venkatarajan Mathura; Amita N Quadros; Fiona C Crawford; Michael J Mullan
Journal:  J Neuroinflammation       Date:  2005-03-11       Impact factor: 8.322

Review 5.  T Lymphocytes and Inflammatory Mediators in the Interplay between Brain and Blood in Alzheimer's Disease: Potential Pools of New Biomarkers.

Authors:  Anna Mietelska-Porowska; Urszula Wojda
Journal:  J Immunol Res       Date:  2017-02-15       Impact factor: 4.818

6.  CA-30, an oligosaccharide fraction derived from Liuwei Dihuang decoction, ameliorates cognitive deterioration via the intestinal microbiome in the senescence-accelerated mouse prone 8 strain.

Authors:  Jianhui Wang; Xi Lei; Zongjie Xie; Xiaorui Zhang; Xiaorui Cheng; Wenxia Zhou; Yongxiang Zhang
Journal:  Aging (Albany NY)       Date:  2019-06-03       Impact factor: 5.682

7.  Inflammation as a potential mediator for the association between periodontal disease and Alzheimer's disease.

Authors:  Amber Watts; Eileen M Crimmins; Margaret Gatz
Journal:  Neuropsychiatr Dis Treat       Date:  2008-10       Impact factor: 2.570

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.